Response to Comments: Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)

This document is a procedural response-to-comments notice regarding Mass Spectrometry (MS) testing in Monoclonal Gammopathy (MG) and does not define clinical coverage criteria, indications, limitations, documentation requirements, or frequency limits. It states the official notice period for the final LCD begins on October 31, 2024, with the final determination effective December 15, 2024. Stakeholder comments were solicited but no policy coverage rules are specified in this document.